Darin E. Jones

High Impact

Associate Professor

Last publication 2026 Last refreshed 2026-05-16

faculty

Pharmaceutical Science, College of Pharmacy

23 h-index 87 pubs 1,264 cited

Biography and Research Information

OverviewAI-generated summary

Darin E. Jones's research focuses on understanding the molecular mechanisms of enzymes involved in DNA repair and replication, with applications in cancer treatment and antiviral drug development. His work utilizes structure-based drug design and chemical screening methodologies, including time-resolved X-ray scattering and high-throughput small-angle X-ray scattering (HT-SAXS), to identify and characterize novel inhibitors.

His publications include studies on inhibitors targeting human uracil-DNA glycosylase and the SARS-CoV-2 Nsp3 macrodomain, drawing insights from human poly(ADP-ribose) glycohydrolase (PARG) structures. Jones also investigates the role of proteins like GRB2 in DNA repair pathways and has explored the effects of compounds such as novobiocin on DNA replication enzymes. His group's research also extends to the radioprotective effects of tocotrienols.

Jones leads a research group and has a scholarly record reflected by an h-index of 23 and 1,239 total citations across 86 publications. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Philip J. Breen, Edward J. Selvik, Shobanbabu Bommagani, and David E. Mery.

Metrics

  • h-index: 23
  • Publications: 87
  • Citations: 1,264

Selected Publications

  • Structural basis for substrate-assisted catalysis and small-molecule inhibition of alphavirus macrodomains (2026)
  • EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
  • Chemical screening by time-resolved X-ray scattering to discover allosteric probes (2024)
    10 citations DOI OpenAlex
  • Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects (2023)
    9 citations DOI OpenAlex
  • Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity (2023)
    29 citations DOI OpenAlex
  • 466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator (2023)
  • Applying HT-SAXS to chemical ligand screening (2022)
    6 citations DOI OpenAlex
  • Analysis of Plant–Plant Interactions Reveals the Presence of Potent Antileukemic Compounds (2022)
    1 citation DOI OpenAlex
  • An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2 (2021)
    8 citations DOI OpenAlex
  • GRB2 enforces homology-directed repair initiation by MRE11 (2021)
    34 citations DOI OpenAlex
  • An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation (2021)
    25 citations DOI OpenAlex
  • Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors (2021)
    59 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

  • Pharmacological Modulation of Poly (ADP-ribose) Metabolism NIH/Nat. Cancer Institute - Pass Through: University of Texas Health Science Center at Houston Principal Investigator
  • A Plug and Play DOE Approach for Emerging Threats: Taskforce 5 US Department of Energy - Pass Through: Lawrence Berkeley National Laboratory Principal Investigator
  • Cellular Functions of Eukaryotic DNA Ligases - Continuation NIH/Nat. Inst. of General Medical Sciences - Pass Through: University of New Mexico Principal Investigator
  • PHARMACOLOGICAL MODULATION OF POLY(ADP-RIBOSE) METABOLISM NIH Co-Principal Investigator
  • Targeting DNA ligase 1 in Ovarian Cancer NIH/Nat. Cancer Institute - Pass Through: University of New Mexico Principal Investigator
  • A Plug and Play DOE Approach for Emerging Threats: Taskforce 5 US Department of Energy - Pass Through: Lawrence Berkeley National Laboratory Principal Investigator
  • Structural Cell Biology of DNA Repair Machines Project 3 - PARP: PAR-dependent, phase-transitioned protein assemblies, and DNA repair. NIH/Nat. Cancer Institute - Pass Through: Lawrence Berkeley National Laboratory Principal Investigator
  • Preventing immune system dysregulation during deep-space missions by Tocofexol, a modified isomer of vitamin E - AA request National Aeronautics & Space Administration - Pass Through: Arkansas Space Grant Consortium Principal Investigator

Collaboration Network

93 Collaborators 21 Institutions 5 Countries

Top Collaborators

View profile →

Similar Researchers

Based on overlapping research topics